Response to Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147.
作者信息
Bergenstal Richard M, Rosenstock Julio, Arakaki Richard F, Prince Melvin J, Qu Yongming, Sinha Vikram P, Howey Daniel C, Jacober Scott J
出版信息
Diabetes Care. 2013 Jul;36(7):e107-8. doi: 10.2337/dc13-0295.
Abstract
摘要
相似文献
1
Response to Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147.对关于以下内容评论的回复：伯根斯塔尔等人。一项针对接受基础胰岛素治疗的2型糖尿病患者，比较新型长效基础胰岛素LY2605541与甘精胰岛素每日一次给药的随机对照研究。《糖尿病护理》2012年；35：2140 - 2147。
Diabetes Care. 2013 Jul;36(7):e107-8. doi: 10.2337/dc13-0295.
2
Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147.评论：贝根斯塔尔等人。一项针对基础胰岛素治疗的2型糖尿病患者，比较新型长效基础胰岛素LY2605541与甘精胰岛素每日一次给药的随机对照研究。《糖尿病护理》2012年；35:2140 - 2147。
Diabetes Care. 2013 Jul;36(7):e106. doi: 10.2337/dc13-0038.
3
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.一项关于每日一次 LY2605541（一种新型长效基础胰岛素）与甘精胰岛素治疗 2 型糖尿病基础胰岛素治疗患者的随机、对照研究。
Diabetes Care. 2012 Nov;35(11):2140-7. doi: 10.2337/dc12-0060. Epub 2012 Oct 9.
4
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.与甘精胰岛素相比，新型长效基础胰岛素 LY2605541 可实现更好的血糖控制和体重减轻：一项 1 型糖尿病的随机交叉研究。
Diabetes Care. 2013 Mar;36(3):522-8. doi: 10.2337/dc12-0067. Epub 2012 Nov 27.
5
Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.与新型长效胰岛素 LY2605541 和甘精胰岛素相比，尽管在 1 型和 2 型糖尿病中都能改善血糖控制，但体重变化却截然不同。
Diabetes Obes Metab. 2014 Apr;16(4):351-6. doi: 10.1111/dom.12223.
6
Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.比较预混胰岛素赖脯胰岛素每日 2 次与甘精胰岛素在基础-餐时胰岛素方案中的疗效：一项前瞻性、随机、开放标签试验。
Diabetes Obes Metab. 2011 Dec;13(12):1149-57. doi: 10.1111/j.1463-1326.2011.01484.x.
7
Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.通过新型长效胰岛素 LY2605541 与甘精胰岛素对比，连续血糖监测可降低血糖变异性和低血糖。
Diabetes Care. 2014;37(3):659-65. doi: 10.2337/dc12-2621. Epub 2013 Nov 6.
8
Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V).中国 2 型糖尿病患者短期强化胰岛素治疗后基于基础胰岛素与每日两次预混胰岛素治疗的疗效和安全性：一项随机对照试验的研究方案（BEYOND V）。
Adv Ther. 2020 Apr;37(4):1675-1687. doi: 10.1007/s12325-020-01265-6. Epub 2020 Mar 4.
9
Basal insulin analogues in the management of diabetes mellitus: What progress have we made?基础胰岛素类似物在糖尿病治疗中的应用：我们取得了哪些进展？
Diabetes Metab Res Rev. 2014 Feb;30(2):104-19. doi: 10.1002/dmrr.2469.
10
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).在 2 型糖尿病的胰岛素初治患者中，德谷胰岛素对比甘精胰岛素：一项为期 1 年、随机、以目标为导向的试验（BEGIN Once Long）。
Diabetes Care. 2012 Dec;35(12):2464-71. doi: 10.2337/dc12-1205. Epub 2012 Oct 5.
本文引用的文献
1
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.与甘精胰岛素相比，新型长效基础胰岛素 LY2605541 可实现更好的血糖控制和体重减轻：一项 1 型糖尿病的随机交叉研究。
Diabetes Care. 2013 Mar;36(3):522-8. doi: 10.2337/dc12-0067. Epub 2012 Nov 27.
2
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.一项关于每日一次 LY2605541（一种新型长效基础胰岛素）与甘精胰岛素治疗 2 型糖尿病基础胰岛素治疗患者的随机、对照研究。
Diabetes Care. 2012 Nov;35(11):2140-7. doi: 10.2337/dc12-0060. Epub 2012 Oct 9.
Zotero 插件